Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Poxel
Biotech
Poxel pivots to midphase rare metabolic disease programs
The new strategy hits pause on plans to start a phase 2b NASH trial and makes no mention of the next steps for phase 3 ready diabetes drug imeglimin.
Nick Paul Taylor
Jul 12, 2021 8:25am
Ahead of possible approval, Metavant backs off imeglimin
Nov 20, 2020 8:30am
Poxel gathers steam as NASH prospect cuts liver fat in phase 2
Oct 1, 2020 11:19am
Poxel posts phase 3 diabetes data ahead of approval decision
Sep 24, 2020 8:00am
Bayer, Poxel, Kymab and more—EuroBiotech Report
Apr 12, 2019 9:45am
Roivant-backed Poxel hits phase 3 diabetes goal, eyes NDA
Apr 9, 2019 9:02am
